Astellas Tralee Biologics Facility on Track as Kerry Technology Park Prepares for €330 Million Construction Phase
Japanese pharmaceutical company Astellas has confirmed that construction of its €330 million biologics sterile fill-finish facility at the Kerry Technology Park in Tralee is progressing on schedule, with the plant expected to be fully operational by 2028 and to create 120 permanent high-value jobs in the Kerry economy — a development that represents one of the most significant pharmaceutical investments in the south-west of Ireland in a generation.
Background
Astellas Pharma Inc., one of Japan's largest pharmaceutical companies, announced its intention to build a new manufacturing facility in Tralee in September 2023, selecting the Kerry Technology Park as the site for what will be a state-of-the-art biologics sterile fill-finish operation. The announcement was welcomed by IDA Ireland, the Kerry County Council, and the local business community as a transformative investment that would diversify the Kerry economy and create high-quality employment in a region that has historically been dependent on agriculture and tourism.
The facility, which will occupy approximately 44.7 acres of the Kerry Technology Park on a greenfield site, is designed to expand Astellas' global capacity for aseptic drug products — the complex, highly regulated manufacturing process used to produce injectable biologics, which are among the most valuable and fastest-growing categories of pharmaceutical products. The plant will reinforce stable production for international supply and accelerate the commercialisation of innovative antibody drugs that are at the cutting edge of modern medicine.
The choice of Tralee as the location for the facility reflects Ireland's established reputation as a centre of pharmaceutical manufacturing excellence. The country is home to nine of the world's ten largest pharmaceutical companies, and the concentration of expertise, regulatory knowledge, and skilled workforce in the sector has made Ireland one of the most attractive locations in the world for pharmaceutical investment.
Key Developments
Astellas has confirmed that construction of the Tralee facility is progressing on schedule, with the main building works advancing on the 17,000 square metre, three-storey structure that will house the fill-finish operations. The company has indicated that it remains on track for the facility to be fully operational by 2028, at which point it will begin commercial production and the 120 permanent jobs will be in place.
The facility has been designed with sustainability at its core, incorporating solar photovoltaic panels, a biomass boiler, and a range of water and energy reduction measures that align with Astellas' corporate climate change mitigation goals. The company has committed to achieving a significant reduction in the facility's carbon footprint relative to comparable manufacturing operations, and has been working with the Sustainable Energy Authority of Ireland to identify additional renewable energy options for the site.
IDA Ireland has confirmed that the Astellas investment is part of a broader pipeline of pharmaceutical and life sciences investments in the south-west of Ireland, with several other companies at advanced stages of planning for facilities in Kerry, Cork, and Limerick. The agency has described the region as one of the most attractive locations in Europe for pharmaceutical manufacturing investment, citing the availability of skilled graduates from the Munster Technological University and University College Cork, the quality of the infrastructure, and the supportive regulatory environment.
Why It Matters
The Astellas investment is significant for Kerry in particular and for the Irish pharmaceutical sector more broadly. Kerry has historically been one of the less industrialised counties in Ireland, with its economy dominated by agriculture, food processing, and tourism. The establishment of a major pharmaceutical manufacturing facility in Tralee represents a diversification of the county's economic base that will have long-term benefits for employment, skills development, and the sustainability of the local economy.
The 120 jobs that the facility will create are high-value positions — in manufacturing, quality assurance, engineering, and management — that will command salaries well above the Kerry average and that will contribute significantly to the local economy through spending on housing, services, and retail. The multiplier effect of 120 well-paid jobs in a county the size of Kerry is substantial, and the facility's presence will also attract ancillary businesses and services to the area.
For the Irish pharmaceutical sector as a whole, the Astellas investment is a further demonstration of Ireland's attractiveness as a manufacturing location. The sector already accounts for over 60% of Ireland's merchandise exports, and the continued inflow of investment from global pharmaceutical companies — attracted by Ireland's skilled workforce, favourable tax environment, and regulatory expertise — is essential to maintaining that position.
Local Impact
In Tralee, the Astellas investment has been welcomed by the business community, the local authority, and the educational institutions that will supply the facility with graduates. The Munster Technological University's Kerry campus, which offers programmes in pharmaceutical science, biotechnology, and engineering, has been working with Astellas to develop curriculum elements that will prepare graduates for the specific requirements of the Tralee facility.
Kerry County Council has been working to ensure that the infrastructure around the Kerry Technology Park — including road access, public transport connections, and utilities — is adequate to support the facility's operations. The council has also been engaging with housing developers to ensure that there is sufficient accommodation available for the workers who will be recruited to the facility, recognising that housing availability is a potential constraint on the facility's ability to attract and retain staff.
What's Next
Construction of the Astellas facility is expected to continue through 2026 and 2027, with the main building works scheduled for completion in early 2028. The company will then begin the process of commissioning and validating the manufacturing equipment — a complex and time-consuming process that is standard in pharmaceutical manufacturing — before beginning commercial production. Recruitment for the 120 permanent positions is expected to begin in 2027, with IDA Ireland and the Munster Technological University supporting the recruitment process. The facility is expected to be fully operational and producing commercial quantities of biologics by the end of 2028.
